Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Common Equity (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Common Equity data on record, last reported at $43.3 million in Q4 2025.

  • For Q4 2025, Common Equity fell 44.7% year-over-year to $43.3 million; the TTM value through Dec 2025 reached $43.3 million, down 44.7%, while the annual FY2025 figure was $43.3 million, 44.7% down from the prior year.
  • Common Equity reached $43.3 million in Q4 2025 per LCTX's latest filing, up from $22.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $123.6 million in Q2 2021 and bottomed at $22.0 million in Q3 2025.
  • Average Common Equity over 5 years is $74.5 million, with a median of $71.3 million recorded in 2023.
  • Peak YoY movement for Common Equity: soared 32.61% in 2021, then tumbled 65.98% in 2025.
  • A 5-year view of Common Equity shows it stood at $119.6 million in 2021, then plummeted by 39.85% to $71.9 million in 2022, then dropped by 13.78% to $62.0 million in 2023, then increased by 26.37% to $78.4 million in 2024, then tumbled by 44.7% to $43.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $43.3 million in Q4 2025, $22.0 million in Q3 2025, and $47.1 million in Q2 2025.